GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Meridian Bioscience VIVO · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.89

-5.03%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2022

Revenue

$333.0m

FY2014FY2022

Net income

$42.5m

FY2014FY2022

Free cash flow

$73.7m

FY2014FY2022

Shareholders' equity

$368.1m

FY2014FY2022

Income statement

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$333.0m$317.9m$253.7m$201.0m$213.6m$200.8m$196.1m$194.8m$188.8m
Gross profit$188.4m$201.1m$156.2m$118.7m$131.0m$124.3m$127.2m$121.9m$117.2m
Research and development$24.3m$23.9m$23.7m$17.8m$16.6m$16.0m$14.2m$12.6m$12.6m
Operating income$75.6m$101.8m$68.0m$38.9m$44.7m$44.8m$53.6m$56.1m$52.4m
Net income$42.5m$71.4m$46.2m$24.4m$23.8m$21.6m$32.2m$35.5m$34.7m
Diluted earnings per share0.961.621.070.570.550.510.760.850.83

Balance sheet

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$463.1m$449.7m$405.3m$325.5m$251.4m$249.8m$252.0m$183.3m$176.9m
Cash and short-term investments$81.5m$49.8m$53.5m$62.4m$59.8m$57.1m$47.2m$50.0m$43.0m
Total liabilities$95.0m$121.4m$157.6m$134.5m$76.0m$80.2m$85.6m$17.4m$15.9m
Debt$25.0m$60.0m$68.8m$75.8m$50.2m$54.6m$58.4m——
Shareholders' equity$368.1m$328.3m$247.6m$191.0m$175.4m$169.6m$166.5m$165.9m$161.0m
Shares outstanding44m44m43m43m43m43m42m42m42m

Cash flow

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations$82.4m$66.9m$48.0m$36.2m$34.8m$41.4m$37.2m$42.8m$38.3m
Capital spending−$8.6m−$18.3m−$3.3m−$3.8m−$4.2m−$4.5m−$4.0m−$4.8m−$7.0m
Free cash flow$73.7m$48.6m$44.7m$32.4m$30.6m$36.9m$33.2m$38.1m$31.3m
Dividends paid———−$10.6m−$21.2m−$24.3m−$33.6m−$33.4m−$32.8m

Latest quarters

By quarter end

Sept 2022Jun 2022Mar 2022Dec 2021Sept 2021Jun 2021Mar 2021Dec 2020
Revenue$65.7m$67.8m$111.2m$88.3m$76.2m$63.5m$85.3m$92.9m
Gross profit$34.0m$36.7m$68.5m$49.2m$44.7m$37.1m$57.8m$61.5m
Operating income$9.0m$9.4m$36.7m$20.6m$14.3m$16.4m$35.2m$35.9m
Net income$5.7m−$7.3m$28.8m$15.3m$6.7m$11.7m$26.3m$26.8m
Diluted earnings per share0.13-0.170.650.350.150.260.600.61
Total assets$463.1m$465.9m$471.8m$458.6m$449.7m$446.6m$439.2m$423.9m
Cash and short-term investments$81.5m$83.5m$76.5m$72.7m$49.8m$70.0m$63.4m$63.2m
Debt$25.0m$25.0m$25.0m$50.0m$60.0m$50.0m$50.0m$58.8m
Shareholders' equity$368.1m$365.5m$374.6m$345.2m$328.3m$322.2m$309.5m$278.9m

Financial ratios

Data as of 2 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin—268.8%-100.8%-11.9%27.6%—
Operating margin—-245312.5%-380.9%-197.7%-24.1%—
Net margin—-291875.0%-600.6%-217.1%-31.6%—
Return on equity—115.2%-650.2%-102.0%-18.7%—
Return on assets—-124.8%-39.7%-31.7%-9.9%—
Free cash flow yield—33.8%-11.8%6.1%-306.6%—
Revenue growth—-99.6%-60.1%-57.6%——
Earnings growth—91.7%10.4%191.3%——
Current ratio—0.33x0.55x0.93x1.82x—
Debt to equity—-0.52x7.52x0.99x0.53x—
Equity ratio—-108.3%6.1%31.0%52.8%—
Interest coverage—-7.90x-3.80x-5.62x-1.77x—
Buybacks as a share of market value8.4%-282.0%0.0%0.0%-100.0%0.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue18.3%10.6%6.8%
Operating income24.8%11.0%4.2%
Net income20.3%14.5%2.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin59.8%60.1%60.5%61.6%
Operating margin27.3%25.7%24.6%26.1%
Net margin17.5%16.7%15.1%16.4%

Valuation history

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Price to earnings0.21.57.11.50.92.83.63.6
Price to sales0.00.31.30.20.10.30.60.7

Market value over time

30 Jun 2021 to 30 Oct 2026, in USD

$2.24bn$18.0m

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return432%32%61%-91%-55%559%42%-55%-56%6%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 1 Feb 2019.

FY2019FY2018FY2017FY2016FY2015FY2014FY2013FY2012
Paid in the year0.250.500.5750.800.800.790.950.76
  • 3-for-2 split · 14 May 2007
  • 3-for-2 split · 6 Sept 2005
  • 3-for-2 split · 3 Oct 1995
  • 1.03-for-1 split · 21 Nov 1994
  • 1.03-for-1 split · 7 Dec 1993
  • 21-for-20 split · 30 Nov 1992

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.